Bass, Spangenberg Target Diprivan Patent In AIA Review
Hedge fund manager Kyle Bass has teamed up with self-described "patent troll" Erich Spangenberg in an attempt to take down another drug patent, this time targeting Fresenius Kabi USA LLC's anesthetic...To view the full article, register now.
Already a subscriber? Click here to view full article